Overview

Study Evaluating Multiple Ascending Dose in Schizophrenia Patients

Status:
Terminated
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, inpatient, ascending multiple dose study to assess safety and tolerability of SLV-313 SR tablets administered orally to subjects with schizophrenia and schizoaffective disorder.
Phase:
Phase 1
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Collaborator:
Solvay Pharmaceuticals